Last reviewed · How we verify

JW Life Science — Portfolio Competitive Intelligence Brief

JW Life Science pipeline: 1 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
SmofKabiven SmofKabiven marketed Parenteral nutrition emulsion Nutrition support / Critical care
CombiflexOmega CombiflexOmega phase 3
CombiflexOmega peri CombiflexOmega peri phase 3

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Erasmus Medical Center · 1 shared drug class
  2. Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · 1 shared drug class
  3. RWTH Aachen University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for JW Life Science:

Cite this brief

Drug Landscape (2026). JW Life Science — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jw-life-science. Accessed 2026-06-10.

Related